Market revenue in 2023 | USD 89.6 million |
Market revenue in 2030 | USD 139.2 million |
Growth rate | 6.5% (CAGR from 2023 to 2030) |
Largest segment | Drugs |
Fastest growing segment | Drugs |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drugs, Devices |
Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, IQVIA Holdings Inc, Labcorp Holdings Inc, Medpace Holdings Inc, Vial, ProTrials Research, Syneos Health, Worldwide Clinical Trials, ProRelix Research |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic clinical trials market will help companies and investors design strategic landscapes.
Drugs was the largest segment with a revenue share of 75.56% in 2023. Horizon Databook has segmented the UK ophthalmic clinical trials market based on drugs, devices covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UK ophthalmic clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UK ophthalmic clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account